The Attention-Deficit
Hyperactivity Disorder (ADHD) therapeutics market value will rise from $6.9
billion in 2013 to $9.9 billion by 2020, with broadening diagnostic criteria a
key driver of growth, according to ADHD therapeutics to 2020 - Broadened Diagnostic
Criteria and Growing Adult Prevalence to Drive Market Growth despite Patent
Expirations report.
This report states that this
increase, which represents a Compound Annual Growth Rate (CAGR) of 5.3% and
relates to eight major markets (the US, the UK, France, Germany, Spain, Italy,
Japan and Canada), will occur fastest in Japan, due to its high ADHD
prevalence.
Despite the stigma attached
to mental health conditions, this country will witness a more impressive ADHD
treatment market CAGR of 15.7%.
Senior Analyst says: “ADHD
prevalence will rise steadily across the major markets, from approximately 15
million cases in 2013 to just over 18 million by 2020. However, diagnosis rates
are particularly low outside of the US, as the disorder is still treated with
considerable skepticism.
“Debate remains about the
fear of under- or over-diagnosis, the causes and legitimacy of ADHD as a
condition, and the skew towards greater prevalence in the US. Research has
suggested that ADHD is just as prevalent in other countries as in the US, but
it is significantly more recognized in this market.”
Prior notes that this trend
is expected to change over the coming decade, due largely to an increased
recognition of adult ADHD.
The fifth edition of The
Diagnostic and Statistical Manual of Mental Disorders, which was published in
2013, broadened the diagnostic criteria for ADHD, recognizing that impairment
from symptoms of the disorder may develop in later life.
Analyst says: “These
developments herald the final acceptance of adult ADHD in a clinical setting
and mean that many people who met the ‘partial remission’ criteria will now
meet the full criteria, leading to an increase in diagnosis.
“However, the continuing
reluctance of many patients to seek treatment for mental health conditions will
be a barrier to ADHD diagnosis rates, and consequently to any further market
growth.”
ADHD therapeutics to 2020 -
Broadened Diagnostic Criteria and Growing Adult Prevalence to Drive Market
Growth despite Patent Expirations report provides analysis of the currently
marketed Attention-Deficit Hyperactivity Disorder (ADHD) drugs, including
recent sales figures and safety and efficacy data, across eight major markets
(8MM: the US, Canada, UK, France, Germany, Italy, Spain and Japan). It also
provides comprehensive reviews of the ADHD drugs pipeline and in-depth,
multi-scenario forecasts for ADHD therapeutics in the 8MM up to 2018.
Spanning over 91 pages, “ADHD Therapeutics to 2020 - Broadened Diagnostic Criteria
and Growing Adult Prevalence to Drive Market Growth despite Patent Expirations”
report covering the Introduction, Marketed Products, ADHD Pipeline, Market Forecast to
2020, Deals and Strategic Consolidations, Appendix.
Know
more about this report: http://mrr.cm/ZX9
No comments:
Post a Comment
Note: only a member of this blog may post a comment.